Trials / Unknown
UnknownNCT03288571
Use of Wharton Jelly in Diabetic Nephropathy
The Safety of Intra-parenchymal Wharton Jelly Mesenchymal Stem Cell Injection in the Treatment of Diabetic Nephropathy
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Sophia Al-Adwan · Academic / Other
- Sex
- All
- Age
- 35 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Wharton Jelly derived Mesenchymal stem cells will be injected in the renal parenchyma of patients with Diabetic Nephropathy
Detailed description
Mesenchymal stem cells (MSCs) are to be isolated from Umbilical cord Wharton's Jelly obtained after normal full term delivery. Samples will be tested for any bacterial or fungal growth as well as endotoxin and mycoplasma. The specific markers for MSCs identification will be analyzed by flow cytometry. Cell suspension will then be injected in the renal parenchyma of patients diagnosed with diabetic nephropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Wharton Jelly Mesenchymal stem cells | Wharton Jelly Mesenchymal stem cells will be injected in the renal parenchyma |
Timeline
- Start date
- 2019-11-01
- Primary completion
- 2020-12-01
- Completion
- 2021-01-01
- First posted
- 2017-09-20
- Last updated
- 2019-07-24
Source: ClinicalTrials.gov record NCT03288571. Inclusion in this directory is not an endorsement.